Popular Articles

Renewed Strategic Approach Needed, Says The British Heart Foundation
In response to the inquiry report into "Was the NHS Plan really a blueprint for the NHS - 10 years on?" released by the All Party Parliamentary Group Primary Care & Public Health today. Mubeen Bhutta Policy Manager at the British Heart Foundation said:
generic viagra online
New: Interventional Radiology Coding Users' Guide
The 2009 Interventional Radiology Coding Users" Guide, a comprehensive re for endovascular and interventional procedures and services, is now available in both book and CD formats. This unique reference is made available by the Society of Interventional Radiology, a national organization of physicians, scientists and allied health professionals dedicated to improving public health through disease management and minimally invasive, image-guided therapeutic interventions.
News of the day
Gallup Poll Reflects Cultural, Political Changes In Abortion Views, Opinion Piece Says
"There were all kinds of ways to misunderstand" the meaning of a recent Gallup poll that found for the first time that more U.S. residents identify themselves as "pro-life" than as "pro-choice," Time columnist Nancy Gibbs writes in an opinion piece. Gibbs writes that although Gallup "attributes the new numbers to Republicans purifying their views," that trend is "to be expected" because "when fewer people call themselves Republican, the party condenses into a pool of true believers." According to Gibbs, the real drivers of the shift are "the people in the middle who are constantly weighing which restrictions are reasonable." Gibbs notes a recent Pew poll that found that while "a majority of independents said abortion should be legal in most cases as recently as October, just 44% do so now." This finding "may inspire some introspection on the part of the political operatives in both parties who attribute the Republicans" present frailty to its orthodoxy on social issues," Gibbs says, adding that the GOP"s "message, on abortion at least, may be closer to mainstream than Democrats care to acknowledge."Gibbs continues, "I think the numbers, inadequate and simplified though they may be, reflect deeper changes -- some generational, some legal, some technological." She writes that people younger than age 30 "are more opposed to abortion than those older" and that she "wonder[s] if younger women are now sure enough of their sexual autonomy and their choices generally, that they don"t view limits on abortion as attacks on their overall freedom." At the same time, "the political context" has changed, Gibbs says. She adds, "The very meaning of the labels adjusts; calling yourself pro-choice at a time when a liberal Democratic President and allies in Congress are lifting abortion restraints may imply no qualms at all, and that"s not where most people are." She continues, "People always want to apply the brakes to whichever side has the momentum" because the "stakes are too high, the pain too private ... to see the issue treated as an ideological toy or fundraising tool." Gibbs concludes, "President Obama got in trouble in his talk last August with Rick Warren for saying that the question of when life begins was "above my pay grade." But just because he was glib doesn"t mean he was wrong" (Gibbs, Time, 5/18).
Mental Health

BioLineRx Initiates Phase I/II Trial Of BL-5010, A Novel Formulation For The Non Surgical Removal Of Skin Lesions

BioLineRx, a drug development company with products in advanced clinical and pre-clinical testing, today announced the initiation of a Phase I/II clinical trial aimed at assessing the safety and efficacy of BL-5010, a novel formulation for the non surgical removal of skin lesions. The open-label, single arm trial will be conducted in 60 patients with seborrheic keratosis in Germany and the Netherlands. The objectives of the study are to determine the safety and tolerability of the BL-5010 formulation and to assess its efficacy in completely removing the lesion. In addition, we will assess BL-5010"s efficacy in preserving the cellular structure of the lesion for subsequent histological examination. The study is scheduled to start in June, 2009. Interim results from the first 25 patients are expected in the fourth quarter of 2009. "BL-5010 is an exciting product in development that may offer a fast, safe and painless way to eliminate skin lesions," stated Morris C. Laster, M.D., CEO of BioLineRx. "We look forward to accelerating development of this novel formulation." About Skin Lesions and Current Removal Methods Clinically diagnosed benign skin lesions are very common and often constitute a cosmetic and sometimes functional annoyance. They tend to be wounded, bleed or become infected. In addition, when located in exposed parts of the body, they present a severe aesthetic problem. Skin lesions are currently removed using destructive methods including cryotherapy (liquid nitrogen) and electro-coagulation (electrical burning) or via surgery. Cryotherapy and electro-coagulation are used for the removal of benign superficial lesions and are often associated with pain and inflammation that can last for several months. Surgical removal is used when histological examination of the lesion is required. It has to be conducted under sterile conditions and requires anesthesia. In addition, the cosmetic outcome of surgical removal is less than desirable. The number of lesion removal procedures and in particular non-surgical procedures has substantially increased in recent years. USA and European market size is estimated at $580 mm per year. About BL-5010 BL-5010 is a novel formulation composed of approved components. BL-5010 offers an alternative to painful, invasive and expensive removal treatments including surgery, cryotherapy or laser treatment. Because the treatment is non-invasive, it poses minimal infection risk and no need for anesthesia or bandaging. BL-5010 is applied topically on the lesion for a few minutes, and causes the lesion to gradually dry out and shed from the skin within 1-3 weeks. In addition, we believe that the unique composition of BL-5010 will allow the preservation of the lesion"s cellular structure, enabling histological examination. BL-5010 is being developed by BioLineRx, Ltd. under a worldwide exclusive license from Innovative Pharmaceutical Concepts, Ltd., a privately held company led by Prof. Pinchas Burstein. BioLineRx


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):